Unicycive's Drug Application Accepted by FDA with Target Date Set
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 29 2026
0mins
Should l Buy UNCY?
Source: Newsfilter
- FDA Acceptance: Unicycive's New Drug Application for oxylanthanum carbonate (OLC) has been accepted by the FDA, with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026, marking a significant advancement in chronic kidney disease treatment.
- Strong Financial Position: Unicycive ended 2025 with an unaudited cash position of $41.3 million, which is expected to support its OLC commercialization activities into 2027, ensuring ongoing investment in research and market launch efforts.
- Clinical Research Support: The NDA for OLC is backed by data from three clinical studies, demonstrating its potential in treating hyperphosphatemia, and the FDA raised no concerns regarding its safety or efficacy data, bolstering market confidence.
- Strong Market Demand: Hyperphosphatemia is prevalent among end-stage renal disease patients, with over 450,000 individuals annually requiring medication to control phosphate levels, and the launch of OLC will provide a crucial treatment option for this large patient population, indicating significant market potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UNCY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UNCY
Wall Street analysts forecast UNCY stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.450
Low
21.00
Averages
35.80
High
60.00
Current: 6.450
Low
21.00
Averages
35.80
High
60.00
About UNCY
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kuehn Law Investigates Unicycive Executives for Fiduciary Breaches
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. breached their fiduciary duties to shareholders, with allegations in a federal securities lawsuit claiming the company overstated its readiness to meet FDA manufacturing compliance requirements.
- False Statement Allegations: The lawsuit asserts that insiders at Unicycive failed to disclose that their ability to satisfy FDA requirements was overstated, resulting in public statements being materially false and misleading at all relevant times.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased UNCY stock prior to March 29, 2024, to contact the firm promptly to enforce their rights, emphasizing that shareholder voices are crucial for the integrity and fairness of financial markets.
- Legal Cost Commitment: Kuehn Law commits to covering all case costs without charging investor clients, highlighting its dedication to protecting shareholder rights and encouraging active participation to secure the future of their investments.
See More
Kuehn Law Investigates Unicycive Executives for Fiduciary Breaches
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. breached their fiduciary duties to shareholders, with allegations in a federal securities lawsuit claiming the company overstated its readiness to meet FDA manufacturing compliance requirements.
- False Statement Allegations: The lawsuit asserts that Unicycive exaggerated the regulatory prospects of the OLC NDA, resulting in public statements that were materially false and misleading at all relevant times.
- Shareholder Rights Protection: Kuehn Law urges shareholders who own UNCY stock purchased before March 29, 2024, to contact the firm promptly to enforce their rights, indicating that there may be limited time for legal action.
- Legal Service Commitment: Kuehn Law promises to cover all case costs without charging investor clients, emphasizing the importance of shareholder participation in maintaining the integrity and fairness of financial markets.
See More
Unicycive Therapeutics Reports FY Loss and Cash Position
- Disappointing Earnings: Unicycive Therapeutics reported a fiscal year GAAP EPS of -$1.67, missing expectations by $0.02, indicating ongoing challenges in profitability that may affect investor confidence.
- Cash Position: As of March 30, 2026, the company's unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, suggesting a reasonable liquidity position to support operations in the near term.
- Sufficient Funding Assurance: The company believes it has adequate resources to fund planned operations into 2027, reflecting management's confidence in future growth despite current financial pressures.
- FDA Review Progress: Unicycive's resubmitted marketing application for its kidney disease drug has been granted FDA review, which could enhance its market competitiveness if successful, despite the current disappointing financial performance.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The U.S. District Court for the Southern District of New York partially denied ASP Isotopes Inc. (NASDAQ: ASPI) and its executives' motion to dismiss, allowing the securities fraud class action to proceed, indicating significant legal exposure for the company.
- False Statement Allegations: The lawsuit alleges that the company and its executives made materially false and misleading statements regarding their uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which could have long-term financial repercussions for the firm.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, suggesting that legal proceedings may provide remedies for affected investors and enhance market confidence in corporate governance.
- Future Risk Assessment: As the lawsuit progresses, ASP Isotopes may face increased regulatory scrutiny and a crisis of market trust, impacting its future financing capabilities and business development strategies, necessitating close monitoring of subsequent developments.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The class action against ASP Isotopes (NASDAQ: ASPI) continues after the Southern District of New York partially denied the defendants' motion to dismiss, indicating potential legal liabilities for the company and its executives, which could undermine investor confidence.
- False Statement Allegations: The lawsuit alleges that the company made materially false and misleading statements regarding its uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which may have long-term implications for its financial health.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, highlighting the potential impact of legal actions on corporate governance structures.
- Market Reaction: As the lawsuit progresses, investor confidence in the company's future may wane, leading to stock price volatility, reflecting the market's heightened scrutiny of the company's transparency and compliance.
See More
Unicycive's Drug Application Accepted by FDA with Target Date Set
- FDA Acceptance: Unicycive's New Drug Application for oxylanthanum carbonate (OLC) has been accepted by the FDA, with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026, marking a significant advancement in chronic kidney disease treatment.
- Strong Financial Position: Unicycive ended 2025 with an unaudited cash position of $41.3 million, which is expected to support its OLC commercialization activities into 2027, ensuring ongoing investment in research and market launch efforts.
- Clinical Research Support: The NDA for OLC is backed by data from three clinical studies, demonstrating its potential in treating hyperphosphatemia, and the FDA raised no concerns regarding its safety or efficacy data, bolstering market confidence.
- Strong Market Demand: Hyperphosphatemia is prevalent among end-stage renal disease patients, with over 450,000 individuals annually requiring medication to control phosphate levels, and the launch of OLC will provide a crucial treatment option for this large patient population, indicating significant market potential.
See More
Kuehn Law Investigates Unicycive Executives for Fiduciary Breaches
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. breached their fiduciary duties to shareholders, with allegations in a federal securities lawsuit claiming the company overstated its readiness to meet FDA manufacturing compliance requirements.
- False Statement Allegations: The lawsuit asserts that insiders at Unicycive failed to disclose that their ability to satisfy FDA requirements was overstated, resulting in public statements being materially false and misleading at all relevant times.
- Shareholder Rights Protection: Kuehn Law urges shareholders who purchased UNCY stock prior to March 29, 2024, to contact the firm promptly to enforce their rights, emphasizing that shareholder voices are crucial for the integrity and fairness of financial markets.
- Legal Cost Commitment: Kuehn Law commits to covering all case costs without charging investor clients, highlighting its dedication to protecting shareholder rights and encouraging active participation to secure the future of their investments.
See More
Kuehn Law Investigates Unicycive Executives for Fiduciary Breaches
- Investigation Background: Kuehn Law, PLLC is investigating whether certain officers and directors of Unicycive Therapeutics, Inc. breached their fiduciary duties to shareholders, with allegations in a federal securities lawsuit claiming the company overstated its readiness to meet FDA manufacturing compliance requirements.
- False Statement Allegations: The lawsuit asserts that Unicycive exaggerated the regulatory prospects of the OLC NDA, resulting in public statements that were materially false and misleading at all relevant times.
- Shareholder Rights Protection: Kuehn Law urges shareholders who own UNCY stock purchased before March 29, 2024, to contact the firm promptly to enforce their rights, indicating that there may be limited time for legal action.
- Legal Service Commitment: Kuehn Law promises to cover all case costs without charging investor clients, emphasizing the importance of shareholder participation in maintaining the integrity and fairness of financial markets.
See More
Unicycive Therapeutics Reports FY Loss and Cash Position
- Disappointing Earnings: Unicycive Therapeutics reported a fiscal year GAAP EPS of -$1.67, missing expectations by $0.02, indicating ongoing challenges in profitability that may affect investor confidence.
- Cash Position: As of March 30, 2026, the company's unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, suggesting a reasonable liquidity position to support operations in the near term.
- Sufficient Funding Assurance: The company believes it has adequate resources to fund planned operations into 2027, reflecting management's confidence in future growth despite current financial pressures.
- FDA Review Progress: Unicycive's resubmitted marketing application for its kidney disease drug has been granted FDA review, which could enhance its market competitiveness if successful, despite the current disappointing financial performance.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The U.S. District Court for the Southern District of New York partially denied ASP Isotopes Inc. (NASDAQ: ASPI) and its executives' motion to dismiss, allowing the securities fraud class action to proceed, indicating significant legal exposure for the company.
- False Statement Allegations: The lawsuit alleges that the company and its executives made materially false and misleading statements regarding their uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which could have long-term financial repercussions for the firm.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, suggesting that legal proceedings may provide remedies for affected investors and enhance market confidence in corporate governance.
- Future Risk Assessment: As the lawsuit progresses, ASP Isotopes may face increased regulatory scrutiny and a crisis of market trust, impacting its future financing capabilities and business development strategies, necessitating close monitoring of subsequent developments.
See More
ASP Isotopes Class Action Survives Dismissal Motion
- Class Action Progress: The class action against ASP Isotopes (NASDAQ: ASPI) continues after the Southern District of New York partially denied the defendants' motion to dismiss, indicating potential legal liabilities for the company and its executives, which could undermine investor confidence.
- False Statement Allegations: The lawsuit alleges that the company made materially false and misleading statements regarding its uranium enrichment technology prior to September 2024, raising approximately $18.6 million without actual testing, which may have long-term implications for its financial health.
- Investor Rights Protection: Investors who purchased ASP Isotopes securities before September 26, 2024, can seek corporate reforms and fund recovery, highlighting the potential impact of legal actions on corporate governance structures.
- Market Reaction: As the lawsuit progresses, investor confidence in the company's future may wane, leading to stock price volatility, reflecting the market's heightened scrutiny of the company's transparency and compliance.
See More
Unicycive's Drug Application Accepted by FDA with Target Date Set
- FDA Acceptance: Unicycive's New Drug Application for oxylanthanum carbonate (OLC) has been accepted by the FDA, with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026, marking a significant advancement in chronic kidney disease treatment.
- Strong Financial Position: Unicycive ended 2025 with an unaudited cash position of $41.3 million, which is expected to support its OLC commercialization activities into 2027, ensuring ongoing investment in research and market launch efforts.
- Clinical Research Support: The NDA for OLC is backed by data from three clinical studies, demonstrating its potential in treating hyperphosphatemia, and the FDA raised no concerns regarding its safety or efficacy data, bolstering market confidence.
- Strong Market Demand: Hyperphosphatemia is prevalent among end-stage renal disease patients, with over 450,000 individuals annually requiring medication to control phosphate levels, and the launch of OLC will provide a crucial treatment option for this large patient population, indicating significant market potential.
See More
